GIOVANNI MENDONCA BARIANI

(Fonte: Lattes)
Índice h a partir de 2011
10
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico

Filtros

Limpar filtros

Configurações

Revista / Livro: European Journal of Cancer ×

Resultados de Busca

Agora exibindo 1 - 2 de 2
  • conferenceObject
    Factors associated with mortality rates of patients with advanced cancer admitted to a specialized intensive care unit
    (2013) BARIANI, G. M.; CASTRIA, T. B.; ANDRADE, A. M.; FARIA, L. D.; SILVA, D. F.; BRAGHIROLI, M. I.; MIRANDA, V. C.; FEDE, A. B.; HAJJAR, L.; RIECHELMANN, R.
  • article 3 Citação(ões) na Scopus
    Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study
    (2022) MAIO, Michele; AMONKAR, Mayur M.; NORQUIST, Josephine M.; ASCIERTO, Paolo A.; MANZYUK, Ludmila; MOTOLA-KUBA, Daniel; PENEL, Nicolas; CASSIER, Philippe A.; BARIANI, Giovanni M.; ACOSTA, Ana De Jesus; DOI, Toshihiko; LONGO, Federico; MILLER JR., Wilson H.; OH, Do-Youn; GOTTFRIED, Maya; WANG, Ruixue; NORWOOD, Kevin; MARABELLE, Aurelien
    Background: In the KEYNOTE-158 study (NCT02628067), pembrolizumab showed a high objective response rate and durable clinical benefit for patients with previously treated, unresectable/metastatic microsatellite instability-high (MSI- H)/mismatch repair-deficient (dMMR) non-colorectal solid tumours. We present health-related quality of life (HRQoL) results from the MSI-H/dMMR population (cohort K). Patients and methods: Eligible patients had previously treated MSI-H/dMMR advanced non-colorectal solid tumours, measurable disease per RECIST v1.1, and ECOG performance status <= 1. Patients received pembrolizumab 200 mg Q3W for 35 cycles (2 years). The EORTC Quality of Life Questionnaire (QLQ-C30) and EQ-5D-3L were administered at baseline, at regular intervals throughout treatment, and 30 days after treatment discontinuation. Prespecified analyses (exploratory endpoints) included the magnitude of change from baseline to post-baseline timepoints in all patients and by the best overall response for QLQ-C30 global health status (GHS)/QoL, QLQ-C30 functional/symptom scales/items, and EQ-5D-3L visual analogue scale (VAS) score. Results: At data cutoff (October 5, 2020), 351 patients were enrolled, of whom 311 and 315 completed baseline QLQ-C30 and EQ-5D-3L questionnaires, respectively. QLQ-C30 GHS/QoL scores improved from baseline to week 9 (mean [95% CI] change, 3.07 [0.19-5.94]), then remained stable or improved by week 111, with greater improvements observed in patients with a best response of complete response (CR) or partial response (PR) (10.85 [6.36-15.35]). Patients with CR/PR showed improvements in physical (5.58 [1.91-9.25]), role (9.88 [3.80-15.97]), emotional (5.62 [1.56-9.68]), and social (8.33 [2.70-13.97]) functioning, and stable cognitive functioning (1.74 [-1.45 to 4.94]). Conclusions: Pembrolizumab generally improved or preserved HRQoL in patients with previously treated MSI-H/dMMR advanced non-colorectal solid tumours. (c) 2022 Merck Sharp & Dohme Corp., a subsidiary Merck & Co., Inc., Kenilworth, NJ, USA and The Author(s).